Generation of Pax1/PAX1-Specific Monoclonal Antibodies

This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.

In a depilated mouse model, this study found that blocking CXCL4 activity with an anti-CXCL4 monoclonal antibody promoted hair growth by inducing an earlier anagen phase, delaying hair follicle regression, and altering expression of genes and proteins related to hair growth and cell proliferation.

This study suggests that a specific region upstream of the TGF-β1 gene may play a key role in androgenetic alopecia by regulating gene expression in a cell-specific manner.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.

This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.